We read with interest the article by Carrie and colleagues in The Lancet Oncology describing the long-term outcomes of the GETUG-AFU 16 trial. After a median follow-up of 112 months (IQR 102–123), metastasis-free survival was improved after 6 months of androgen deprivation therapy combined with salvage radiation therapy versus salvage radiotherapy alone in patients with biochemically recurrent prostate cancer without persisting prostate-specific antigen after radical prostatectomy (hazard ratio 0·73, 95% CI 0·54–0·98; p=0·0339). Patients were grouped by risk (of biological or metastatic recurrence or prostate cancer-related death, according to a combination of several risk factors (GETUG group criteria); however, metastasis-free survival did not differ between low-risk and high-risk subgroups.

中文翻译：

---

前列腺切除术后雄激素剥夺疗法加抢救放疗。

我们感兴趣地阅读了Carrie及其同事在《柳叶刀肿瘤学》上的文章，该文章描述了GETUG-AFU 16试验的长期结果。在中位随访112个月（IQR 102-123）后，对于生化复发性前列腺癌患者且未坚持前列腺特异性治疗的患者，雄激素剥夺治疗联合挽救放疗相比单独进行挽救放疗6个月后，无转移生存率得到改善前列腺癌根治术后的抗原（危险比0·73，95％CI 0·54-0·98； p = 0·0339）。根据多种风险因素（GETUG组标准）的组合，将患者按风险（生物或转移性复发或前列腺癌相关死亡）分组；但是，低风险和高风险亚组的无转移生存率无差异。